神経ステロイド
出典: フリー百科事典『ウィキペディア（Wikipedia）』 (2023/01/01 07:31 UTC 版)
神経ステロイド[1]（Neurosteroid）は、内因性または外因性のステロイドで、リガンド依存性のイオンチャネルや細胞表面の受容体との相互作用により、神経の興奮性を急速に変化させる事から、神経刺激性ステロイドまたは神経活性ステロイド（Neuroactive steroid）とも呼ばれている[2][3]。神経ステロイドという言葉は、フランスの生理学者であるÉtienne-Émile Baulieuによって作られた造語で、脳内で合成されるステロイドを指す[4][5]。神経刺激性ステロイドとは、脳内で合成されたり、内分泌腺で合成されたりして、血流に乗って脳に到達し、脳機能に影響を与えるステロイドを指す[6]。神経刺激性ステロイドという言葉は、1992年にSteven PaulとRobert Purdyによって初めて作られた。これらのステロイドの中には、神経細胞膜の受容体への作用に加えて、核内ステロイドホルモン受容体を介して遺伝子発現に作用するものもある。神経ステロイドは、鎮静作用からてんかん[7]や外傷性脳損傷の治療に至るまで、幅広い臨床応用が期待されている[8][9]。内因性神経ステロイドであるアロプレグナノロンの合成アナログであるガナキソロンは、てんかんの治療薬として研究されている[10]。
- ^ neurogenic effects
- ^ “neurosteroidの意味・使い方・読み方 | Weblio英和辞書”. ejje.weblio.jp. 2021年10月9日閲覧。
- ^ Paul SM, Purdy RH (March 1992). “Neuroactive steroids”. FASEB Journal 6 (6): 2311-2322. doi:10.1096/fasebj.6.6.1347506. PMID 1347506.
- ^ Lan NC, Gee KW (December 1994). “Neuroactive steroid actions at the GABAA receptor”. Hormones and Behavior 28 (4): 537-544. doi:10.1006/hbeh.1994.1052. PMID 7729823.
- ^ a b c d e f Reddy DS (2010). “Neurosteroids: endogenous role in the human brain and therapeutic potentials”. Progress in Brain Research 186: 113-137. doi:10.1016/B978-0-444-53630-3.00008-7. PMC 3139029. PMID 21094889.
- ^ Reddy DS, Rogawski MA (2012). "Neurosteroids - Endogenous Regulators of Seizure Susceptibility and Role in the Treatment of Epilepsy". In Noebels JL, Avoli M, Rogawski MA, et al. (eds.). Jasper's Basic Mechanisms of the Epilepsies [Internet]. 4th edition. Bethesda (MD): National Center for Biotechnology Information (US). National Center for Biotechnology Information (US).
- ^ a b Srivastava DP, Waters EM, Mermelstein PG, Kramár EA, Shors TJ, Liu F (November 2011). "Rapid estrogen signaling in the brain: implications for the fine-tuning of neuronal circuitry". The Journal of Neuroscience. 31 (45): 16056–16063. doi:10.1523/JNEUROSCI.4097-11.2011. PMC 3245715. PMID 22072656。
- ^ a b Reddy DS, Rogawski MA (April 2009). “Neurosteroid replacement therapy for catamenial epilepsy”. Neurotherapeutics 6 (2): 392-401. doi:10.1016/j.nurt.2009.01.006. PMC 2682439. PMID 19332335.
- ^ Morrow AL (October 2007). “Recent developments in the significance and therapeutic relevance of neuroactive steroids--Introduction to the special issue”. Pharmacology & Therapeutics 116 (1): 1-6. doi:10.1016/j.pharmthera.2007.04.003. PMC 2047816. PMID 17531324.
- ^ Dubrovsky BO (February 2005). “Steroids, neuroactive steroids and neurosteroids in psychopathology”. Progress in Neuro-Psychopharmacology & Biological Psychiatry 29 (2): 169-192. doi:10.1016/j.pnpbp.2004.11.001. PMID 15694225.
- ^ a b Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS (Jan 2013). “Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI)”. Epilepsy Research 103 (1): 2-30. doi:10.1016/j.eplepsyres.2012.10.001. PMID 23219031.
- ^ Rougé-Pont F, Mayo W, Marinelli M, Gingras M, Le Moal M, Piazza PV (July 2002). "The neurosteroid allopregnanolone increases dopamine release and dopaminergic response to morphine in the rat nucleus accumbens". The European Journal of Neuroscience. 16 (1): 169–173. doi:10.1046/j.1460-9568.2002.02084.x. PMID 12153544. S2CID 9953445。
- ^ a b c Frye CA (December 2009). “Neurosteroids' effects and mechanisms for social, cognitive, emotional, and physical functions”. Psychoneuroendocrinology 34 Suppl 1: S143-161. doi:10.1016/j.psyneuen.2009.07.005. PMC 2898141. PMID 19656632.
- ^ Pinna G, Costa E, Guidotti A (February 2005). “Changes in brain testosterone and allopregnanolone biosynthesis elicit aggressive behavior”. Proceedings of the National Academy of Sciences of the United States of America 102 (6): 2135-2140. Bibcode: 2005PNAS..102.2135P. doi:10.1073/pnas.0409643102. PMC 548579. PMID 15677716.
- ^ Terán-Pérez G, Arana-Lechuga Y, Esqueda-León E, Santana-Miranda R, Rojas-Zamorano JÁ, Velázquez Moctezuma J (October 2012). "Steroid hormones and sleep regulation". Mini Reviews in Medicinal Chemistry. 12 (11): 1040–1048. doi:10.2174/138955712802762167. PMID 23092405。
- ^ Patte-Mensah C, Meyer L, Taleb O, Mensah-Nyagan AG (February 2014). “Potential role of allopregnanolone for a safe and effective therapy of neuropathic pain”. Progress in Neurobiology 113: 70-78. doi:10.1016/j.pneurobio.2013.07.004. PMID 23948490.
- ^ Hénin J, Salari R, Murlidaran S, Brannigan G (2014). "A predicted binding site for cholesterol on the GABAA receptor". Biophys. J. 106 (9): 1938–1949. Bibcode:2014BpJ...106.1938H. doi:10.1016/j.bpj.2014.03.024. PMC 4017285. PMID 24806926。
- ^ Levitan, Irena; Singh, Dev K.; Rosenhouse-Dantsker, Avia (2014). “Cholesterol binding to ion channels”. Frontiers in Physiology 5: 65. doi:10.3389/fphys.2014.00065. ISSN 1664-042X. PMC 3935357. PMID 24616704.
- ^ Paul, S. M.; Doherty, J. J.; Robichaud, A. J.; Belfort, G. M.; Chow, B. Y.; Hammond, R. S.; Crawford, D. C.; Linsenbardt, A. J. et al. (2013). “The Major Brain Cholesterol Metabolite 24(S)-Hydroxycholesterol Is a Potent Allosteric Modulator of N-Methyl-D-Aspartate Receptors”. Journal of Neuroscience 33 (44): 17290-17300. doi:10.1523/JNEUROSCI.2619-13.2013. ISSN 0270-6474. PMC 3812502. PMID 24174662.
- ^ Christopher H. Hawkes; Richard L. Doty (12 February 2009). The Neurology of Olfaction. Cambridge University Press. pp. 37-. ISBN 978-0-521-68216-9
- ^ a b Monti-Bloch L, Jennings-White C, Dolberg DS, Berliner DL (1994). “The human vomeronasal system”. Psychoneuroendocrinology 19 (5-7): 673-686. doi:10.1016/0306-4530(94)90049-3. PMID 7938363.
- ^ a b Liebowitz MR, Salman E, Nicolini H, Rosenthal N, Hanover R, Monti L (June 2014). “Effect of an acute intranasal aerosol dose of PH94B on social and performance anxiety in women with social anxiety disorder”. The American Journal of Psychiatry 171 (6): 675-682. doi:10.1176/appi.ajp.2014.12101342. PMID 24700254.
- ^ Marx CE, Bradford DW, Hamer RM, Naylor JC, Allen TB, Lieberman JA, Strauss JL, Kilts JD (September 2011). “Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence”. Neuroscience 191: 78-90. doi:10.1016/j.neuroscience.2011.06.076. PMID 21756978.
- ^ Baulieu E, Schumacher M (2000). “Progesterone as a neuroactive neurosteroid, with special reference to the effect of progesterone on myelination”. Steroids 65 (10-11): 605-612. doi:10.1016/s0039-128x(00)00173-2. PMID 11108866.
- ^ Thomas P, Pang Y (2012). “Membrane progesterone receptors: evidence for neuroprotective, neurosteroid signaling and neuroendocrine functions in neuronal cells”. Neuroendocrinology 96 (2): 162-171. doi:10.1159/000339822. PMC 3489003. PMID 22687885.
- ^ Agís-Balboa RC, Pinna G, Zhubi A, Maloku E, Veldic M, Costa E, Guidotti A (September 2006). "Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis". Proceedings of the National Academy of Sciences of the United States of America. 103 (39): 14602–14607. Bibcode:2006PNAS..10314602A. doi:10.1073/pnas.0606544103. PMC 1600006. PMID 16984997。
- ^ Mellon SH, Griffin LD (2002). “Neurosteroids: biochemistry and clinical significance”. Trends in Endocrinology and Metabolism 13 (1): 35-43. doi:10.1016/S1043-2760(01)00503-3. PMID 11750861.
- ^ Benarroch EE (March 2007). “Neurosteroids: endogenous modulators of neuronal excitability and plasticity”. Neurology 68 (12): 945-947. doi:10.1212/01.wnl.0000257836.09570.e1. PMID 17372131.
- ^ Vallée M, Mayo W, Koob GF, Le Moal M (2001). "Neurosteroids in learning and memory processes". International Review of Neurobiology. 46: 273–320. doi:10.1016/s0074-7742(01)46066-1. ISBN 9780123668462. PMID 11599303。
- ^ a b Engel SR, Grant KA (2001). “Neurosteroids and behavior”. International Review of Neurobiology 46: 321-348. doi:10.1016/S0074-7742(01)46067-3. ISBN 9780123668462. PMID 11599304.
- ^ a b King SR (2008). “Emerging roles for neurosteroids in sexual behavior and function”. Journal of Andrology 29 (5): 524-533. doi:10.2164/jandrol.108.005660. PMID 18567641.
- ^ Joshi S, Rajasekaran K, Kapur J (June 2013). “GABAergic transmission in temporal lobe epilepsy: the role of neurosteroids”. Experimental Neurology 244: 36-42. doi:10.1016/j.expneurol.2011.10.028. PMC 3319002. PMID 22101060.
- ^ a b Girdler SS, Klatzkin R (October 2007). “Neurosteroids in the context of stress: implications for depressive disorders”. Pharmacology & Therapeutics 116 (1): 125-139. doi:10.1016/j.pharmthera.2007.05.006. PMC 2650267. PMID 17597217.
- ^ a b Bali A, Jaggi AS (Jan 2014). “Multifunctional aspects of allopregnanolone in stress and related disorders”. Progress in Neuro-Psychopharmacology & Biological Psychiatry 48: 64-78. doi:10.1016/j.pnpbp.2013.09.005. PMID 24044974.
- ^ Gunn BG, Cunningham L, Mitchell SG, Swinny JD, Lambert JJ, Belelli D (Jan 2015). “GABAA receptor-acting neurosteroids: a role in the development and regulation of the stress response”. Frontiers in Neuroendocrinology 36: 28-48. doi:10.1016/j.yfrne.2014.06.001. PMC 4349499. PMID 24929099.
- ^ a b Bäckström T, Andersson A, Andreé L, Birzniece V, Bixo M, Björn I, Haage D, Isaksson M, Johansson IM, Lindblad C, Lundgren P, Nyberg S, Odmark IS, Strömberg J, Sundström-Poromaa I, Turkmen S, Wahlström G, Wang M, Wihlbäck AC, Zhu D, Zingmark E (December 2003). "Pathogenesis in menstrual cycle-linked CNS disorders". Annals of the New York Academy of Sciences. 1007 (1): 42–53. Bibcode:2003NYASA1007...42B. doi:10.1196/annals.1286.005. PMID 14993039. S2CID 20995334。
- ^ Guille C, Spencer S, Cavus I, Epperson CN (July 2008). “The role of sex steroids in catamenial epilepsy and premenstrual dysphoric disorder: implications for diagnosis and treatment”. Epilepsy & Behavior 13 (1): 12-24. doi:10.1016/j.yebeh.2008.02.004. PMC 4112568. PMID 18346939.
- ^ Finocchi C, Ferrari M (May 2011). “Female reproductive steroids and neuronal excitability”. Neurological Sciences 32 Suppl 1: S31-35. doi:10.1007/s10072-011-0532-5. PMID 21533709.
- ^ Genazzani AR, Bernardi F, Monteleone P, Luisi S, Luisi M (2000). “Neuropeptides, neurotransmitters, neurosteroids, and the onset of puberty”. Annals of the New York Academy of Sciences 900 (1): 1-9. Bibcode: 2000NYASA.900....1G. doi:10.1111/j.1749-6632.2000.tb06210.x. PMID 10818386.
- ^ Melcangi RC, Panzica G, Garcia-Segura LM (September 2011). “Neuroactive steroids: focus on human brain”. Neuroscience 191: 1-5. doi:10.1016/j.neuroscience.2011.06.024. hdl:10261/61590. PMID 21704130.
- ^ Andréen L, Sundström-Poromaa I, Bixo M, Nyberg S, Bäckström T (August 2006). "Allopregnanolone concentration and mood--a bimodal association in postmenopausal women treated with oral progesterone". Psychopharmacology. 187 (2): 209–221. doi:10.1007/s00213-006-0417-0. PMID 16724185. S2CID 1933116。
- ^ a b Bäckström T, Haage D, Löfgren M, Johansson IM, Strömberg J, Nyberg S, Andréen L, Ossewaarde L, van Wingen GA, Turkmen S, Bengtsson SK (September 2011). "Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons". Neuroscience. 191: 46–54. doi:10.1016/j.neuroscience.2011.03.061. PMID 21600269. S2CID 38928854。
- ^ a b Andréen L, Nyberg S, Turkmen S, van Wingen G, Fernández G, Bäckström T (September 2009). "Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABAA modulators". Psychoneuroendocrinology. 34 (8): 1121–1132. doi:10.1016/j.psyneuen.2009.02.003. PMID 19272715. S2CID 22259026。
- ^ a b Bäckström T, Bixo M, Johansson M, Nyberg S, Ossewaarde L, Ragagnin G, Savic I, Strömberg J, Timby E, van Broekhoven F, van Wingen G (February 2014). "Allopregnanolone and mood disorders". Progress in Neurobiology. 113: 88–94. doi:10.1016/j.pneurobio.2013.07.005. PMID 23978486. S2CID 207407084。
- ^ Maurice T, Urani A, Phan VL, Romieu P (2001). “The interaction between neuroactive steroids and the sigma1 receptor function: behavioral consequences and therapeutic opportunities”. Brain Res. Brain Res. Rev. 37 (1-3): 116-132. doi:10.1016/s0165-0173(01)00112-6. PMID 11744080.
- ^ a b c d e Su TP, London ED, Jaffe JH (1988). “Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems”. Science 240 (4849): 219-221. Bibcode: 1988Sci...240..219S. doi:10.1126/science.2832949. PMID 2832949.
- ^ a b c d e Takebayashi M, Hayashi T, Su TP (2004). “A perspective on the new mechanism of antidepressants: neuritogenesis through sigma-1 receptors”. Pharmacopsychiatry 37 Suppl 3: S208-213. doi:10.1055/s-2004-832679. PMID 15547787.
- ^ Rogawski MA, Reddy DS, 2004. Neurosteroids: endogenous modulators of seizure susceptibility. In: Rho, J.M., Sankar, R., Cavazos, J. (Eds.), Epilepsy: Scientific Foundations of Clinical Practice. Marcel Dekker, New York, 2004;319-355.
- ^ Kokate TG, Yamaguchi S, Pannell LK, Rajamani U, Carroll DM, Grossman AB, Rogawski MA (November 1998). “Lack of anticonvulsant tolerance to the neuroactive steroid pregnanolone in mice”. The Journal of Pharmacology and Experimental Therapeutics 287 (2): 553-558. PMID 9808680.
- ^ Reddy DS, Rogawski MA (December 2000). “Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself”. The Journal of Pharmacology and Experimental Therapeutics 295 (3): 1241-1248. PMID 11082461.
- ^ Orrin Devinsky; Steven Schachter; Steven Pacia (1 January 2005). Complementary and Alternative Therapies for Epilepsy. Demos Medical Publishing. pp. 378-. ISBN 978-1-934559-08-6
- ^ “Brexanolone - Sage Therapeutics - AdisInsight”. 2021年10月10日閲覧。
- ^ “Our Programs - SAGE Therapeutics”. web.archive.org (2017年7月29日). 2021年10月10日閲覧。
- ^ Griebel G, Holmes A (September 2013). “50 years of hurdles and hope in anxiolytic drug discovery”. Nature Reviews. Drug Discovery 12 (9): 667-687. doi:10.1038/nrd4075. PMC 4176700. PMID 23989795.
- ^ “Pregnenolone methyl ether - Mapreg - AdisInsight”. 2021年10月10日閲覧。
- ^ Duchossoy Y, David S, Baulieu EE, Robel P (2011). “Treatment of experimental spinal cord injury with 3β-methoxy-pregnenolone”. Brain Res. 1403: 57-66. doi:10.1016/j.brainres.2011.05.065. PMID 21704982.
- ^ Bianchi M, Baulieu EE (2012). “3β-Methoxy-pregnenolone (MAP4343) as an innovative therapeutic approach for depressive disorders”. Proc. Natl. Acad. Sci. U.S.A. 109 (5): 1713-1718. Bibcode: 2012PNAS..109.1713B. doi:10.1073/pnas.1121485109. PMC 3277154. PMID 22307636.
- ^ Baulieu ÉÉ (2015). "From steroid hormones to depressive states and senile dementias: New mechanistic, therapeutical and predictive approaches". Comptes Rendus Biologies. 338 (8–9): 613–616. doi:10.1016/j.crvi.2015.06.003. PMID 26251072。
- ^ Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, Guidotti A (March 1998). “Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine”. Proceedings of the National Academy of Sciences of the United States of America 95 (6): 3239-2344. Bibcode: 1998PNAS...95.3239U. doi:10.1073/pnas.95.6.3239. PMC 19726. PMID 9501247.
- ^ Pinna G, Costa E, Guidotti A (June 2006). “Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake”. Psychopharmacology 186 (3): 362-372. doi:10.1007/s00213-005-0213-2. PMID 16432684.
- ^ Dhir A, Rogawski MA (April 2012). “Role of neurosteroids in the anticonvulsant activity of midazolam”. British Journal of Pharmacology 165 (8): 2684-2691. doi:10.1111/j.1476-5381.2011.01733.x. PMC 3423249. PMID 22014182.
- ^ Usami N, Yamamoto T, Shintani S, Ishikura S, Higaki Y, Katagiri Y, Hara A (April 2002). “Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines”. Biological & Pharmaceutical Bulletin 25 (4): 441-445. doi:10.1248/bpb.25.441. PMID 11995921.
[続きの解説]
「神経ステロイド」の続きの解説一覧
- 1 神経ステロイドとは
- 2 神経ステロイドの概要
- 3 作用
- 4 生理活性
- 5 神経ステロイドへのベンゾジアゼピンの作用
このページでは「ウィキペディア」から神経ステロイドを検索した結果を表示しています。
Weblioに収録されているすべての辞書から神経ステロイドを検索する場合は、下記のリンクをクリックしてください。
全ての辞書から神経ステロイド を検索
Weblioに収録されているすべての辞書から神経ステロイドを検索する場合は、下記のリンクをクリックしてください。
全ての辞書から神経ステロイド を検索 - 神経ステロイドのページへのリンク
